These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 10397482)

  • 1. Perceived benefits of and barriers to participation in a phase I/II colon cancer chemoprevention trial.
    Hudmon KS; Love RR; Chamberlain RM
    J Cancer Educ; 1999; 14(2):83-7. PubMed ID: 10397482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
    Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
    Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
    Meyskens FL; Gerner EW
    Clin Cancer Res; 1999 May; 5(5):945-51. PubMed ID: 10353725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Participants' perceptions of a phase I colon cancer chemoprevention trial.
    Hudmon KS; Stoltzfus C; Chamberlain RM; Lorimor RJ; Steinbach G; Winn RJ
    Control Clin Trials; 1996 Dec; 17(6):494-508. PubMed ID: 8974209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine.
    Carbone PP; Douglas JA; Larson PO; Verma AK; Blair IA; Pomplun M; Tutsch KD
    Cancer Epidemiol Biomarkers Prev; 1998 Oct; 7(10):907-12. PubMed ID: 9796636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-study aspirin intake and factors motivating participation in a colorectal cancer chemoprevention trial.
    Sample DA; Sinicrope PS; Wargovich MJ; Sinicrope FA
    Cancer Epidemiol Biomarkers Prev; 2002 Mar; 11(3):281-5. PubMed ID: 11895878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colon cancer: a USA viewpoint.
    Lipkin M
    IARC Sci Publ; 1996; (136):53-61. PubMed ID: 8791116
    [No Abstract]   [Full Text] [Related]  

  • 9. Summary of recommendations for colonic biomarker studies of candidate chemopreventive compounds in phase II clinical trials.
    Lipkin M
    J Cell Biochem Suppl; 1994; 19():94-8. PubMed ID: 7823612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part II.
    Moyad MA
    Urol Oncol; 2004; 22(6):472-7. PubMed ID: 15610864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cohorts with familial disposition for colon cancers in chemoprevention trials.
    Burt RW
    J Cell Biochem Suppl; 1996; 25():131-5. PubMed ID: 9027609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conducting chemoprevention clinical trials: challenges and solutions.
    Richmond E; O'Mara A
    Semin Oncol; 2010 Aug; 37(4):402-6. PubMed ID: 20816509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk biomarkers and current strategies for cancer chemoprevention.
    Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
    J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part I.
    Moyad MA
    Urol Oncol; 2004; 22(6):466-71. PubMed ID: 15610863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Women's feedback on a chemopreventive trial for cervical dysplasia.
    Bieniasz ME; Underwood D; Bailey J; Ruffin MT
    Appl Nurs Res; 2003 Feb; 16(1):22-8. PubMed ID: 12624859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical development plan: ursodiol.
    J Cell Biochem Suppl; 1996; 26():258-68. PubMed ID: 9154182
    [No Abstract]   [Full Text] [Related]  

  • 17. Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial.
    Loehberg CR; Jud SM; Haeberle L; Heusinger K; Dilbat G; Hein A; Rauh C; Dall P; Rix N; Heinrich S; Buchholz S; Lex B; Reichler B; Adamietz B; Schulz-Wendtland R; Beckmann MW; Fasching PA
    Breast Cancer Res Treat; 2010 May; 121(1):101-10. PubMed ID: 20306293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of a telephone survey to recruit health maintenance organization members into a tamoxifen chemoprevention trial.
    Daly M; Seay J; Balshem A; Lerman C; Engstrom P
    Cancer Epidemiol Biomarkers Prev; 1992; 1(5):413-6. PubMed ID: 1305474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical evaluation of cancer chemoprevention agents: defining and contrasting phase I, II, and III objectives.
    Goodman GE
    Cancer Res; 1992 May; 52(9 Suppl):2752s-2757s. PubMed ID: 1563007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention.
    Gerner EW; Meyskens FL; Goldschmid S; Lance P; Pelot D
    Amino Acids; 2007 Aug; 33(2):189-95. PubMed ID: 17396214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.